Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MDWD Stock Forecast 2026-2027
$17.04
Current Price
$218.48M
Market Cap
Buy 6
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to MDWD Price Targets
+128.9%
To High Target of $39.00
+87.8%
To Median Target of $32.00
+46.7%
To Low Target of $25.00
MDWD Price Momentum
-11.7%
1 Week Change
-10.6%
1 Month Change
-11.6%
1 Year Change
-7.7%
Year-to-Date Change
-24.3%
From 52W High of $22.51
+20.5%
From 52W Low of $14.14
📊 TOP ANALYST CALLS
Did MDWD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if MediWound is one of their latest high-conviction picks.
Latest MDWD Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, MDWD has a bullish consensus with a median price target of $32.00 (ranging from $25.00 to $39.00). The overall analyst rating is Strong Buy (9.7/10). Currently trading at $17.04, the median forecast implies a 87.8% upside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Chase Knickerbocker at Craig-Hallum, projecting a 128.9% upside. Conversely, the most conservative target is provided by Swayampakula Ramakanth at HC Wainwright & Co., suggesting a 46.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MDWD Analyst Ratings
6
Buy
0
Hold
0
Sell
MDWD Price Target Range
Low
$25.00
Average
$32.00
High
$39.00
Current: $17.04
Latest MDWD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MDWD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 21, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $36.00 |
| May 22, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $31.00 |
| Mar 20, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $25.00 |
| Feb 28, 2025 | Craig-Hallum | Chase Knickerbocker | Buy | Initiates | $39.00 |
| Jan 10, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $25.00 |
| Nov 27, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $25.00 |
| Oct 11, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $28.00 |
| Aug 15, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $28.00 |
| Jul 16, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $28.00 |
| May 30, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $28.00 |
| Mar 22, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $28.00 |
| Jan 16, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $28.00 |
| Nov 22, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $26.00 |
| Sep 21, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $26.00 |
| Aug 17, 2023 | Oppenheimer | Outperform | Maintains | $N/A | |
| Aug 17, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 31, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $23.00 |
| May 31, 2023 | Oppenheimer | Francois Brisebois | Outperform | Reiterates | $63.00 |
| Mar 17, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $23.00 |
| Jan 4, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $23.00 |
MediWound Ltd. (MDWD) Competitors
The following stocks are similar to MediWound based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
MediWound Ltd. (MDWD) Financial Data
MediWound Ltd. has a market capitalization of $218.48M with a P/E ratio of -5.6x. The company generates $20.93M in trailing twelve-month revenue with a -98.4% profit margin.
Revenue growth is +24.7% quarter-over-quarter, while maintaining an operating margin of -120.2% and return on equity of -48.8%.
Valuation Metrics
Market Cap
$218.48M
Enterprise Value
$170.09M
P/E Ratio
-5.6x
PEG Ratio
0.1x
Price/Sales
10.2x
Growth & Margins
Revenue Growth (YoY)
+24.7%
Gross Margin
+16.5%
Operating Margin
-120.2%
Net Margin
-98.4%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+27.0%
Current Ratio
2.6x
Debt/Equity
16.5x
ROE
-48.8%
ROA
-17.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
MediWound Ltd. (MDWD) Business Model
About MediWound Ltd.
What They Do
Specializes in next-generation enzymatic therapeutics.
Business Model
MediWound Ltd. develops, manufactures, and commercializes topical biologic therapies designed for non-surgical tissue repair. The company generates revenue primarily through the sale of its flagship product, NexoBrid, which treats deep thermal burns, along with advancing other therapeutic candidates like EscharEx for chronic wounds and MW005 for basal cell carcinoma.
Additional Information
MediWound focuses on addressing unmet medical needs in burn care, chronic wound management, and dermatologic oncology, positioning itself as a key player in the evolving biopharmaceutical sector. It has received regulatory approval for its products in major markets such as the U.S., EU, and Japan.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
111
CEO
Country
Israel
IPO Year
2014
Website
www.mediwound.comMediWound Ltd. (MDWD) Latest News & Analysis
Latest News
Quick Summary
MediWound has released a corporate update and financial outlook in preparation for the upcoming J.P. Morgan Healthcare Conference.
Why It Matters
MediWound's corporate update and financial outlook may influence stock performance and investor sentiment, especially ahead of a significant industry event like the J.P. Morgan Healthcare Conference.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
MediWound announced new clinical data showing that NexoBrid® effectively prevents traumatic tattoos following abrasion and blast injuries.
Why It Matters
MediWound's positive clinical data on NexoBrid® enhances its market potential, indicating possible growth in revenue and investor confidence in the company's future performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
MediWound Ltd. (MDWD) will hold its Q3 2025 earnings call on November 20, 2025, at 8:30 AM EST, featuring key executives and analysts from Lifesci Advisors and TD Cowen.
Why It Matters
MediWound's Q3 earnings call may reveal key financial performance metrics and strategic insights, influencing investor confidence and stock price movements.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
MediWound Ltd. reports ongoing enrollment in the VALUE Phase III trial for EscharEx, completion of NexoBrid facility commissioning, and Q3 2025 revenue of $5.4M, up 23% YoY.
Why It Matters
MediWound's ongoing trials and facility expansion signal growth potential, while a strengthened balance sheet and increased revenue enhance financial stability, appealing to investors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
MediWound (MDWD) reported a quarterly loss of $0.24 per share, beating the Zacks estimate of $0.81, and improved from a loss of $0.98 per share a year prior.
Why It Matters
MediWound's smaller-than-expected quarterly loss indicates improved performance, potentially boosting investor confidence and affecting stock valuation positively.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
MediWound Ltd. will report its Q3 2025 financial results on November 20 at 8:30 a.m. ET, with a conference call and webcast scheduled for the announcement.
Why It Matters
MediWound's upcoming financial results could impact stock performance, indicating company health and future growth potential, influencing investor sentiment and market positioning.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About MDWD Stock
What is MediWound Ltd.'s (MDWD) stock forecast for 2026?
Based on our analysis of 10 Wall Street analysts, MediWound Ltd. (MDWD) has a median price target of $32.00. The highest price target is $39.00 and the lowest is $25.00.
Is MDWD stock a good investment in 2026?
According to current analyst ratings, MDWD has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $17.04. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MDWD stock?
Wall Street analysts predict MDWD stock could reach $32.00 in the next 12 months. This represents a 87.8% increase from the current price of $17.04. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is MediWound Ltd.'s business model?
MediWound Ltd. develops, manufactures, and commercializes topical biologic therapies designed for non-surgical tissue repair. The company generates revenue primarily through the sale of its flagship product, NexoBrid, which treats deep thermal burns, along with advancing other therapeutic candidates like EscharEx for chronic wounds and MW005 for basal cell carcinoma.
What is the highest forecasted price for MDWD MediWound Ltd.?
The highest price target for MDWD is $39.00 from Chase Knickerbocker at Craig-Hallum, which represents a 128.9% increase from the current price of $17.04.
What is the lowest forecasted price for MDWD MediWound Ltd.?
The lowest price target for MDWD is $25.00 from Swayampakula Ramakanth at HC Wainwright & Co., which represents a 46.7% increase from the current price of $17.04.
What is the overall MDWD consensus from analysts for MediWound Ltd.?
The overall analyst consensus for MDWD is bullish. Out of 10 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $32.00.
How accurate are MDWD stock price projections?
Stock price projections, including those for MediWound Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 3:33 AM UTC